BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 19683876)

  • 1. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
    Morganti AG; Balducci M; Salvati M; Esposito V; Romanelli P; Ferro M; Calista F; Digesù C; Macchia G; Ianiri M; Deodato F; Cilla S; Piermattei A; Valentini V; Cellini N; Cantore GP
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):92-7. PubMed ID: 19683876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).
    Massaccesi M; Ferro M; Cilla S; Balducci M; Deodato F; Macchia G; Valentini V; Morganti AG
    Int J Clin Oncol; 2013 Oct; 18(5):784-91. PubMed ID: 22892797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
    Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
    Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma.
    Truc G; Bernier V; Mirjolet C; Dalban C; Mazoyer F; Bonnetain F; Blanchard N; Lagneau É; Maingon P; Noël G
    Cancer Radiother; 2016 May; 20(3):193-8. PubMed ID: 27117900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
    Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
    Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
    Beauchesne P; Quillien V; Faure G; Bernier V; Noel G; Quetin P; Gorlia T; Carnin C; Pedeux R
    Int J Cancer; 2016 Mar; 138(6):1538-44. PubMed ID: 26501997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme.
    Reddy K; Gaspar LE; Kavanagh BD; Chen C
    J Med Imaging Radiat Oncol; 2014 Dec; 58(6):714-21. PubMed ID: 24975917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma.
    Uto M; Mizowaki T; Ogura K; Arakawa Y; Mineharu Y; Miyamoto S; Hiraoka M
    Int J Clin Oncol; 2016 Dec; 21(6):1023-1029. PubMed ID: 27384182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
    Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
    J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-Operative Accelerated-Hypofractionated Chemoradiation With Volumetric Modulated Arc Therapy and Simultaneous Integrated Boost in Glioblastoma: A Phase I Study (ISIDE-BT-2).
    Ferro M; Ferro M; Macchia G; Cilla S; Buwenge M; Re A; Romano C; Boccardi M; Picardi V; Cammelli S; Cucci E; Mignogna S; Di Lullo L; Valentini V; Morganti AG; Deodato F
    Front Oncol; 2020; 10():626400. PubMed ID: 33692944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.
    Chang SM; Lamborn KR; Malec M; Larson D; Wara W; Sneed P; Rabbitt J; Page M; Nicholas MK; Prados MD
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):353-7. PubMed ID: 15380566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.
    McDonald MW; Shu HK; Curran WJ; Crocker IR
    Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):130-6. PubMed ID: 20399036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.
    Passoni P; Reni M; Cattaneo GM; Slim N; Cereda S; Balzano G; Castoldi R; Longobardi B; Bettinardi V; Gianolli L; Gusmini S; Staudacher C; Calandrino R; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1000-6. PubMed ID: 24267968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
    Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.
    Ammirati M; Chotai S; Newton H; Lamki T; Wei L; Grecula J
    J Clin Neurosci; 2014 Apr; 21(4):633-7. PubMed ID: 24380758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.